What Checkpoint Surgical does

Checkpoint Surgical, Inc. is a Cleveland, Ohio–based (Independence, Ohio headquarters) privately held medical device company founded in 2009 that develops, manufactures, and sells products used by surgeons to locate, evaluate, and protect peripheral nerves during surgical procedures. The company is organized around a "nerve care" franchise spanning three product categories: intraoperative nerve stimulators (CHECKPOINT GUARDIAN Model 9095, CHECKPOINT GEMINI Model 9092, CHECKPOINT Model 9094, and CHECKPOINT HEAD & NECK Model 9394), surgical instruments (CHECKPOINT EDGE Nerve Cutting Kit Model 9250), and biomaterial implants (CHECKPOINT ACMShield dehydrated placental membrane allograft, NeuroShield chitosan membrane, ProVeil soft tissue barrier, and CHECKPOINT AxioCor flexible nerve conduit). All CHECKPOINT stimulators use the company's proprietary biphasic waveform technology, which the company advertises as safe for prolonged or repeated stimulation without diminished response.

The company generates revenue predominantly through direct hardware and biomaterial sales to hospitals and ambulatory surgical centers via a sales-led go-to-market motion staffed by clinical and technical representatives. Surgeons — including orthopedic, neurosurgical, and plastic/reconstructive specialists — are the primary clinical users, with the company also supporting referral pathways into emerging procedures such as Targeted Muscle Reinnervation (TMR) for post-amputation pain. Product adoption is supported by an investment in clinical education resources including a virtual lecture series, virtual course library, nerve manuals, surgeon interviews, and ongoing clinical trials (FASTR-TEN, PHINEST, BES Therapy, PHONES). The company has secured FDA 510(k) clearances for the GEMINI stimulator and NeuroShield chitosan membrane (K190246), ISO 13485:2016 certification, and a CE Mark for European market access.

Checkpoint Surgical has raised approximately $48.7 million across nine funding rounds since 2009, with a $16 million equity financing in August 2021 led by River Cities Capital (now RC Capital) alongside First Analysis, JumpStart Inc., and Mutual Capital Partners, and a $4 million exempt offering in mid-2024. In August 2021 the company also acquired NeuroShield to expand its biomaterial portfolio. Leadership is anchored by CEO Derek Lewis, Founder/Executive Advisor Leonard M. Cosentine, and CFO Laura Keck, with the company operating from a 51–100 person organization focused commercially on the United States and regulatory-ready for Europe through its CE Mark.

Name

Checkpoint Surgical

Legal name

Checkpoint Surgical, Inc.

Website

https://checkpointsurgical.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Checkpoint Surgical is a Cleveland-based medical device company that develops and sells intraoperative nerve stimulators, biomaterial implants, and surgical instruments used by surgeons to locate, evaluate, and protect peripheral nerves during surgical procedures.

Ownership category

akta.pro rank

Product category

Peripheral Nerve Surgery Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industries

Neural & Spinal Cord Regeneration (HLAAAGAI), Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB), Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)

Keywords

• Nerve stimulation devices
• Peripheral nerve surgery
• Intraoperative surgical devices
• Surgical biomaterial allografts
• Nerve repair products

Headquarters

HQ city

Cleveland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Checkpoint Surgical generates revenue through the sale of medical devices including nerve stimulators, biomaterial implants, and specialized surgical instruments for peripheral nerve surgery.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Checkpoint Surgical manufactures and sells intraoperative nerve stimulation devices, biomaterial allografts, and specialized surgical instruments used by surgeons to locate, evaluate, and protect peripheral nerves during surgical procedures. The portfolio spans nerve stimulators (GUARDIAN, GEMINI, CHECKPOINT, HEAD & NECK), the EDGE nerve cutting kit, and biomaterial barriers (ACMShield placental membrane, NeuroShield chitosan membrane, ProVeil soft tissue barrier, AxioCor flexible nerve conduit) covering the nerve care pathway from identification through repair and healing.

Product overview

Checkpoint Surgical is a medical device company offering a portfolio of intraoperative nerve stimulation devices, biomaterial implants, and specialized surgical instruments for peripheral nerve surgery. The product portfolio includes three main stimulator product lines: CHECKPOINT GUARDIAN (Model 9095) and CHECKPOINT GEMINI (Model 9092) for nerve stimulation, and the original CHECKPOINT (Model 9094) Nerve Stimulator/Locator. The company also provides specialized instruments like the CHECKPOINT EDGE Nerve Cutting Kit for surgical preparation, and biomaterial products including CHECKPOINT ACMShield (dehydrated placental membrane allograft), NeuroShield chitosan membrane, and ProVeil soft tissue barriers. All CHECKPOINT stimulators utilize biphasic waveform technology, described as safe for prolonged or repeated stimulation without diminished response.

Differentiator

Problem solved

Functional benefit

Brands

• CHECKPOINT GUARDIAN: Nerve Stimulator product line
• CHECKPOINT GEMINI
• CHECKPOINT ACMShield
• CHECKPOINT EDGE

Products and services

• CHECKPOINT GUARDIAN (Model 9095)

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• MiMedx: MiMedx manufactures dehydrated amniotic membrane allografts (e.g., EpiFix, AmnioFix) used as surgical barriers and wound coverings — directly overlapping with Checkpoint's ACMShield dehydrated placental membrane allograft in surgical soft tissue barrier applications.
• AxoGen: AxoGen is the leading pure-play peripheral nerve repair company, offering nerve grafts, connectors, and caps — directly overlapping with Checkpoint's nerve repair and conduit (AxioCor) portfolio across the same surgical customer base of plastic, orthopedic, and reconstructive surgeons.
• Integra LifeSciences: Integra offers nerve repair products (NeuraGen nerve guides, NeuraWrap) and regenerative tissue technologies that compete directly with Checkpoint's AxioCor conduit and ACMShield biomaterial lines, serving the same peripheral nerve surgery market.

Broad incumbents

• Stryker: Stryker is a large orthopedic and surgical instruments incumbent whose extremities and sports medicine franchises overlap with Checkpoint's orthopedic nerve surgery customer base, and could expand into nerve-specific instruments over time.
• Medtronic: Medtronic is a dominant incumbent in implantable neurostimulation (spinal cord, deep brain, peripheral nerve stimulation systems) and neuromonitoring, providing the broad competitive backdrop against which Checkpoint's intraoperative peripheral nerve stimulators compete for surgeon mindshare and OR shelf space.
• Boston Scientific: Boston Scientific operates a sizable neuromodulation franchise (Precision, Spectra, Vercise) and competes for peripheral nerve stimulation budgets; its scale and existing hospital contracts make it a key competitor for Checkpoint's intraoperative nerve stimulation accounts.
• Natus Medical: Natus Medical supplies neurology-focused diagnostic and monitoring equipment used in surgical and clinical nerve assessment, an adjacent competitor for intraoperative nerve monitoring budgets that hospitals allocate alongside stimulators.
• Abbott (Neuromodulation): Abbott's neuromodulation business (Proclaim DRG, BurstDR, Prodigy) targets dorsal root ganglion and spinal cord stimulation, adjacent to peripheral nerve applications and competing for the same neurology and pain-medicine procedure budgets as Checkpoint.

Emerging players

• Polyganics: Polyganics develops bioresorbable nerve repair devices (Neurolac nerve guides) and other tissue regeneration products — a smaller European peer competing in nerve conduits and repair scaffolds similar to Checkpoint's AxioCor and ACMShield.
• Synapse Biomedical: Synapse Biomedical develops neurostimulation devices (including the NeuRx diaphragm pacing system) and EMG-based surgical products — a smaller peer with overlap on intraoperative nerve stimulation and EMG-driven surgical decision-making.

Market position

Competitive moat4 records

Key highlights1 record

Customer concentration

• Xx.com/checkpointstim
• LinkedInlinkedin.com/company/checkpoint-surgical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds9 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Checkpoint Surgical